Mineralys Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

2024-06-03

RADNOR, Pa., June 03, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference, being held in Miami, FL on June 10-13, 2024.

Goldman Sachs 45th Annual Global Healthcare Conference:Date:Tuesday, June 11, 2024Time:4:00pm EDTFormat:Fireside ChatWebcast Link

A live webcast of the fireside chat can be accessed under “News and Events” on the Investor Relations section of the Mineralys website at www.mineralystx.com. A replay of the fireside chat will be available on the Company’s website for approximately 90 days.

About Mineralys Therapeutics

Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by dysregulated aldosterone, including hypertension and CKD. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.

Contact:

Investor Relations

investorrelations@mineralystx.com

Media Relations

Tom Weible

Elixir Health Public Relations

Phone: (1) 515-707-9678

Email: tweible@elixirhealthpr.com

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构